ES2663815T3 - Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales - Google Patents
Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales Download PDFInfo
- Publication number
- ES2663815T3 ES2663815T3 ES12795778.5T ES12795778T ES2663815T3 ES 2663815 T3 ES2663815 T3 ES 2663815T3 ES 12795778 T ES12795778 T ES 12795778T ES 2663815 T3 ES2663815 T3 ES 2663815T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- transfection
- culture
- plasmid
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims abstract description 110
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 100
- 239000013612 plasmid Substances 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000000725 suspension Substances 0.000 claims abstract description 34
- 238000001890 transfection Methods 0.000 claims description 72
- 229920002873 Polyethylenimine Polymers 0.000 claims description 42
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 241000713666 Lentivirus Species 0.000 claims description 29
- 238000004113 cell culture Methods 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 230000002458 infectious effect Effects 0.000 claims description 11
- 238000003146 transient transfection Methods 0.000 claims description 11
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 9
- 101710091045 Envelope protein Proteins 0.000 claims description 7
- 101710188315 Protein X Proteins 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 239000004017 serum-free culture medium Substances 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 139
- 235000010633 broth Nutrition 0.000 description 67
- 108020004414 DNA Proteins 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 239000002245 particle Substances 0.000 description 22
- 101710205625 Capsid protein p24 Proteins 0.000 description 19
- 101710177166 Phosphoprotein Proteins 0.000 description 19
- 101710149279 Small delta antigen Proteins 0.000 description 19
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 19
- 230000001464 adherent effect Effects 0.000 description 14
- 238000004114 suspension culture Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 101710150344 Protein Rev Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- -1 GlutaMAX TM Chemical compound 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563566P | 2011-11-24 | 2011-11-24 | |
| EP11306551 | 2011-11-24 | ||
| EP11306551 | 2011-11-24 | ||
| US201161563566P | 2011-11-24 | ||
| PCT/EP2012/073645 WO2013076309A1 (en) | 2011-11-24 | 2012-11-26 | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663815T3 true ES2663815T3 (es) | 2018-04-17 |
Family
ID=48469165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12795778.5T Active ES2663815T3 (es) | 2011-11-24 | 2012-11-26 | Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20140315294A1 (en22) |
| EP (2) | EP2782997B1 (en22) |
| JP (2) | JP6280869B2 (en22) |
| CN (2) | CN109097398A (en22) |
| AU (1) | AU2012342355B2 (en22) |
| BR (1) | BR112014012600A2 (en22) |
| CA (1) | CA2856455C (en22) |
| CY (1) | CY1120103T1 (en22) |
| DK (1) | DK2782997T3 (en22) |
| ES (1) | ES2663815T3 (en22) |
| HR (1) | HRP20180424T1 (en22) |
| HU (1) | HUE036742T2 (en22) |
| LT (1) | LT2782997T (en22) |
| PL (1) | PL2782997T3 (en22) |
| PT (1) | PT2782997T (en22) |
| RS (1) | RS57066B1 (en22) |
| SG (1) | SG11201402584RA (en22) |
| SI (1) | SI2782997T1 (en22) |
| SM (1) | SMT201800174T1 (en22) |
| WO (1) | WO2013076309A1 (en22) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| FR3010720B1 (fr) * | 2013-09-16 | 2017-08-11 | Genethon | Procede de production de virus enveloppes |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| WO2015097650A1 (en) * | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| EP4316500A3 (en) | 2015-05-13 | 2024-04-10 | CSL Behring Gene Therapy, Inc. | Bio-production of lentiviral vectors |
| CN105483092A (zh) * | 2015-10-10 | 2016-04-13 | 和元生物技术（上海）股份有限公司 | 一种中试化生产重组腺相关病毒的新技术 |
| SG11201806976UA (en) | 2016-02-23 | 2018-09-27 | Immune Design Corp | Multigenome retroviral vector preparations and methods and systems for producing and using same |
| CN109071594A (zh) * | 2016-04-14 | 2018-12-21 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| CN116144500A (zh) | 2016-04-14 | 2023-05-23 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| WO2018064584A1 (en) * | 2016-09-30 | 2018-04-05 | Life Technologies Corporation | Serum-free suspension system for lentiviral production |
| CN106867877A (zh) * | 2017-02-15 | 2017-06-20 | 昆明医科大学第二附属医院 | 一种密闭式慢病毒载体培养装置和培养方法 |
| US11674115B2 (en) | 2017-10-31 | 2023-06-13 | Global Life Sciences Solutions Usa Llc | Flexible bag |
| CN111727251B (zh) | 2017-11-21 | 2024-09-20 | 克里斯珀医疗股份公司 | 用于治疗常染色体显性色素性视网膜炎的材料和方法 |
| CA3084632A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a |
| WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| CN110317832B (zh) | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) * | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| CN108866013B (zh) * | 2018-08-06 | 2021-03-23 | 武汉赛科成科技有限公司 | 一种大规模生产慢病毒的方法 |
| EP3854879A4 (en) * | 2018-09-20 | 2022-06-22 | National University Corporation Tokyo Medical and Dental University | METHOD OF INCREASING THE PRODUCTION OF LENTIVIRUS VECTORS |
| CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
| JP7333930B2 (ja) * | 2019-01-07 | 2023-08-28 | 独立行政法人国立高等専門学校機構 | ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法 |
| JP2022551219A (ja) | 2019-08-23 | 2022-12-08 | ロンザ ウォーカーズヴィル，インコーポレーテッド | レンチウイルスベクターの製造方法および構築物 |
| CN113122501B (zh) * | 2019-12-30 | 2023-06-16 | 重庆精准生物技术有限公司 | 适合大规模临床级病毒载体制备的培养基及其应用 |
| JP2023526348A (ja) * | 2020-05-15 | 2023-06-21 | アイヴェックスソル インコーポレイテッド | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 |
| US20230220417A1 (en) * | 2020-05-26 | 2023-07-13 | Expression Therapeutics, Llc | Lentiviral System |
| KR20230126214A (ko) * | 2020-12-29 | 2023-08-29 | 지앙수 젠스크립트 프로바이오 바이오테크 컴퍼니 리미티드 | 고분산성 hek293t 세포주 및 이의 스크리닝 방법 |
| GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
| US20240425880A1 (en) * | 2021-10-12 | 2024-12-26 | Jiangsu Genscript Probio Biotech Co., Ltd. | Hek293 cell line adapted to serum-free suspension culture and use thereof |
| CA3231011A1 (en) * | 2021-10-19 | 2023-04-27 | Amgen Inc. | Composition and methods for recombinant lentiviral production |
| EP4508198A1 (en) * | 2022-04-11 | 2025-02-19 | Adverum Biotechnologies, Inc. | Optimization of hek293 suspension platform for improved raav titers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| AU2002348151A1 (en) | 2001-11-05 | 2003-05-19 | Genvec, Inc. | Viral vector production methods and compositions |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| EP2307551B1 (en) | 2008-06-18 | 2016-12-14 | Oxford BioMedica (UK) Limited | Purification of retroviral vectors |
| US20110008894A1 (en) | 2009-07-07 | 2011-01-13 | Cayla | Lyophilized plasmid/dna transfection reagent carrier complex |
| US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
| WO2011097447A2 (en) * | 2010-02-04 | 2011-08-11 | Neurologix, Inc. | Production of recombinant virus |
| CA2823639A1 (en) | 2011-01-05 | 2012-07-12 | Expression Therapeutics, Llc | High yield suspension cell line, system, and method for making same |
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
-
2012
- 2012-11-26 EP EP12795778.5A patent/EP2782997B1/en not_active Revoked
- 2012-11-26 JP JP2014542880A patent/JP6280869B2/ja not_active Expired - Fee Related
- 2012-11-26 AU AU2012342355A patent/AU2012342355B2/en not_active Ceased
- 2012-11-26 SI SI201231258T patent/SI2782997T1/en unknown
- 2012-11-26 US US14/359,960 patent/US20140315294A1/en not_active Abandoned
- 2012-11-26 HU HUE12795778A patent/HUE036742T2/hu unknown
- 2012-11-26 BR BR112014012600A patent/BR112014012600A2/pt not_active Application Discontinuation
- 2012-11-26 CN CN201810811238.0A patent/CN109097398A/zh active Pending
- 2012-11-26 RS RS20180365A patent/RS57066B1/sr unknown
- 2012-11-26 LT LTEP12795778.5T patent/LT2782997T/lt unknown
- 2012-11-26 EP EP17210574.4A patent/EP3327119A1/en not_active Withdrawn
- 2012-11-26 CN CN201280058157.9A patent/CN104136605B/zh not_active Expired - Fee Related
- 2012-11-26 PL PL12795778T patent/PL2782997T3/pl unknown
- 2012-11-26 SG SG11201402584RA patent/SG11201402584RA/en unknown
- 2012-11-26 PT PT127957785T patent/PT2782997T/pt unknown
- 2012-11-26 HR HRP20180424TT patent/HRP20180424T1/hr unknown
- 2012-11-26 DK DK12795778.5T patent/DK2782997T3/en active
- 2012-11-26 CA CA2856455A patent/CA2856455C/en active Active
- 2012-11-26 ES ES12795778.5T patent/ES2663815T3/es active Active
- 2012-11-26 SM SM20180174T patent/SMT201800174T1/it unknown
- 2012-11-26 WO PCT/EP2012/073645 patent/WO2013076309A1/en active Application Filing
-
2017
- 2017-10-05 JP JP2017195148A patent/JP2018046828A/ja active Pending
-
2018
- 2018-03-30 CY CY20181100358T patent/CY1120103T1/el unknown
-
2019
- 2019-03-18 US US16/356,005 patent/US20190211360A1/en not_active Abandoned
-
2021
- 2021-09-02 US US17/464,727 patent/US20220235371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104136605B (zh) | 2018-08-14 |
| EP2782997A1 (en) | 2014-10-01 |
| CN109097398A (zh) | 2018-12-28 |
| EP3327119A1 (en) | 2018-05-30 |
| CA2856455C (en) | 2022-08-23 |
| SG11201402584RA (en) | 2014-06-27 |
| JP2018046828A (ja) | 2018-03-29 |
| SI2782997T1 (en) | 2018-04-30 |
| DK2782997T3 (en) | 2018-04-16 |
| JP6280869B2 (ja) | 2018-02-14 |
| PL2782997T3 (pl) | 2018-06-29 |
| WO2013076309A1 (en) | 2013-05-30 |
| RS57066B1 (sr) | 2018-06-29 |
| LT2782997T (lt) | 2018-05-25 |
| HRP20180424T1 (hr) | 2018-06-29 |
| CA2856455A1 (en) | 2013-05-30 |
| JP2014533516A (ja) | 2014-12-15 |
| US20220235371A1 (en) | 2022-07-28 |
| AU2012342355A1 (en) | 2014-07-17 |
| US20190211360A1 (en) | 2019-07-11 |
| EP2782997B1 (en) | 2018-01-10 |
| BR112014012600A2 (pt) | 2017-06-06 |
| CN104136605A (zh) | 2014-11-05 |
| SMT201800174T1 (it) | 2018-07-17 |
| AU2012342355B2 (en) | 2017-10-12 |
| PT2782997T (pt) | 2018-04-09 |
| US20140315294A1 (en) | 2014-10-23 |
| CY1120103T1 (el) | 2018-12-12 |
| HUE036742T2 (hu) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663815T3 (es) | Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales | |
| JP6290106B2 (ja) | ポロキサマーを用いるレトロウイルス形質導入 | |
| ES2842899T3 (es) | Tampones para la estabilización de preparaciones lentivirales | |
| WO2013139300A1 (zh) | 一种重组慢病毒载体制剂 | |
| Totsugawa et al. | Lentiviral transfer of the LacZ gene into human endothelial cells and human bone marrow mesenchymal stem cells | |
| Miyanohara | Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer | |
| US20230183747A1 (en) | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity | |
| JP5778147B2 (ja) | 遺伝子導入方法 | |
| JP2013208107A (ja) | レトロウイルスベクターの製造方法 | |
| US8852915B2 (en) | Method of retrovirus storage | |
| HK1255189A1 (en) | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications | |
| CN115916987A (zh) | 填充床生物反应器中的慢病毒载体制造方法 | |
| Williams-Fegredo | Developing strategies to enhance transfection efficiency and mitigate auto-transduction in transient lentiviral vector bioprocessing | |
| Régulier et al. | Lentiviral-mediated gene transfer to model triplet repeat disorders | |
| Accordino | Lentiviral Vector Production at High Cell Density by Transient Transfection of Suspended Culture HEK Cells | |
| Guy | Microscale characterisation of a manufacturing route for lentiviral vectors | |
| HK1179656A (en) | Gene introduction method |